Cell line · CVCL_0139
Papers134
1 to 20 of 134
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| EIF3I reprograms iron metabolism to promote gastric cancer progression by stabilizing YAP. | Cell Mol Biol Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Activation of ANGPTL4 Drives EBV-Negative Gastric Cancer via Neutrophil Recruitment and NET Release via Stabilizing ANXA5. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level phosphoproteomics reveals calcium/calmodulin-dependent protein kinase kinase 2-driven kinase signaling underlying malignant phenotypes in gastric cancer. | J Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quercetin Attenuates Cisplatin-Induced Nephrotoxicity While Enhancing Antitumor Efficacy in Gastric Cancer via Cell Type-Specific Modulation of the ERK1/2 Pathway. | J Biochem Mol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FTO-Driven m6A Demethylation of TNC Promotes Epithelial-Mesenchymal Transition and Gastric Cancer Metastasis. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Calcitriol alleviates ARID2-deficient gastric cancer metastasis via inhibition of the Wnt/β-catenin signaling pathway. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of L1CAM from gastric epithelial cells and extracellular vesicles promotes Helicobacter pylori-driven cancer progression and invasiveness. | Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| METTL3-Mediated m6A Modification of COL5A2 Inhibits Ferroptosis Through an IGF2BP3-dependent Mechanism in Gastric Cancer. | Technol Cancer Res Treat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutation-Immune Crosstalk Contextualizes CAF-Associated ARPC1A Programs and Cisplatin Response in Gastric Cancer. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| METTL7A Downregulation Drives SLC1A5-Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8+ T Cell Immunity in Gastric Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. | Apoptosis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Long non-coding RNA SOCS2-AS1 inhibits gastric cancer progression via the miR-324-3p/GRIK3 axis: a mechanistic study. | World J Surg Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of 5'-tiRNAGly restores anti-PD-1 immunotherapy efficacy via DLST-mediated OGDHL succinylation in gastric cancer. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0139/papers